

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 26143

Title: Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer

Reviewer's code: 00722674

Reviewer's country: United Kingdom

Science editor: Jing Yu

Date sent for review: 2016-04-04 14:47

Date reviewed: 2016-04-08 06:09

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Dear authors, Congratulations on your work. It is a well organized and written narrative review that I found easy to follow. However, I would welcome a systematic rather than a narrative review. There are a couple of nice figures but no tables that would make it more appealing to the reader. There are a few orthographic mistakes than need to be corrected ("moldels", "that frequency of KRAS mutation", "harboring KRAS G13D mutation", "One of the first approach", "its role as a predictive biomarkers", "together with lack of perspective studies", "PIK3CA mutations seems", "found several information about the role of PTEN", "represent a powerful activators of", "showed an enhanced anticancer effects") Title should contain less than 12 words according to the instructions for authors. Running title is not provided. There are no key words. Figures do not follow the instructions for authors. Sincerely,

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 26143

Title: Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer

Reviewer's code: 02531403

Reviewer's country: Italy

Science editor: Jing Yu

Date sent for review: 2016-04-04 14:47

Date reviewed: 2016-04-20 18:51

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Dear authors, I read with great interest the manuscript n. 26143. This manuscript is well written and illustrated, however, I have some remarks: - Since it is a review, we need to elucidate the inclusion and exclusion criteria of the studies discussed, together with a flow chart describing such criteria - It is better to define "targeted medicine" rather than "precision medicine" in the introduction - Tables of the studies analyzing BRAF, PIK3CA and loss of PTEN, HER2 and HER 3, MET and EGFR mutation are needed for a wider readability - please quote studies about the role of chemoprevention and diet in the setting of RGFR mutations Many Congratulations, Sincerely,

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 26143

Title: Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer

Reviewer's code: 03552056

Reviewer's country: Spain

Science editor: Jing Yu

Date sent for review: 2016-04-04 14:47

Date reviewed: 2016-05-04 12:08

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

It is a well write article about an interesting and controversial topic. I suggest to include and discuss some references as the follows: Sartre Bianchi A, et al. Lancet Oncology PMID 27108243, about the results of the HERCULES trial Segelov E, et al, J Clin Oncol 2016, april 25, regarding cetuximab in KRAS G13D mutant pats. Dienstmann R et al. Cancr Disco 2015; 5: 598-609 discussing the results of SYM004 in refractory CRC. I suggest to include some tables that recapitulate the clinical trials and agents in research to overcome resistance to anti_EGFR